Genomic Health (NASDAQ: GHDX) reported Q4 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $74.5 million versus the consensus estimate of $74.03 million.

GUIDANCE:

Genomic Health sees FY2016 revenue of $320-335 million, versus the consensus of $328.8 million.

For earnings history and earnings-related data on Genomic Health (GHDX) click here.